Venus Remedies is currently trading at Rs. 218.25, up by 7.35 points or 3.49% from its previous closing of Rs. 210.90 on the BSE.
The scrip opened at Rs. 210.90 and has touched a high and low of Rs. 219.40 and Rs. 206.25 respectively. So far 21,772 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 235.80 on 20-Jun-2012 and a 52 week low of Rs. 141.05 on 22-Dec-2011.
Last one week high and low of the scrip stood at Rs. 219.40 and Rs. 202.00 respectively. The current market cap of the company is Rs. 209.59 crore.
The promoters holding in the company stood at 34.71% while Institutions and Non-Institutions held 14.54% and 50.76% respectively.
Venus Remedies has launched for the first a research based product ‘TROIS’ in the Indian markets. This patent protected topical nano-emulsion is developed by using the integrated natural medicine approach to relieve from all kind of arthritic pain.
TROIS is the most effective drug for the treatment of Arthritis and is getting outstanding response in the various markets across India. TROIS is indicated for the treatment of Rain and Inflammation as associated with Osteoarthritis, Rheumatoid arthritis, Juvenile idiopathic arthritis, Gouty arthritis, Ankylosing spondylitis, Psoriatic arthritis, backache, sprain and fibromyalgia.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: